TG 101348, an oral agent, is a potent inhibitor of Janus kinase 2 (JAK-2), developed for the treatment of patients with myeloproliferative diseases including myelofibrosis (MF). TargeGen said
As per the agreement, OctoPlus is expected to develop, making use of its PolyActive technology, in-vivo feasibility, a controlled release formulation of an undisclosed compound. Novartis is expected
To identify selectively interacting proteins of a drug molecule, it is coupled to caprotec’s Capture Compound scaffold and incubated with human cell lysates, subcellular fractions or whole cells.
Remoxy, being developed by King Pharmaceuticals, is a painkiller with a formulation designed to reduce potential risks of unintended use. Apart from this drug, King Pharmaceuticals is also
AstraZeneca said that the court held the ‘314 patent to be non-obvious and properly reissued and it also found that no inequitable conduct was committed by any Shionogi
On June 1, 2010, AMAG had submitted MAA for Feraheme for the treatment of iron deficiency anemia (IDA) in chronic kidney disease patients. AMAG has two partners for
Claros has been preparing its urology product for the European launch and continuing the process to attain regulatory clearance in other markets, including the US. The approval follows
Cubist said that CXA-201, a combined product of CXA-101 and the beta-lactamase inhibitor tazobactam, is being developed by the company as a first-line intravenous therapy for the treatment
As per the terms of the agreement GSK is expected to fully fund and be responsible for all clinical and regulatory development. Additionally, GSK is also expected to
Muparfostat is a multi-targeted cancer therapeutic in late stage development which inhibits both angiogenesis (or tumour promoting) factors such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factors
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.